These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 28000527)

  • 41. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
    Campoli M; Ferrone S
    Oncogene; 2008 Oct; 27(45):5869-85. PubMed ID: 18836468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
    Rondelet G; Wouters J
    Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
    Flower KJ; Ghaem-Maghami S; Brown R
    Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epigenetic drugs as immunomodulators for combination therapies in solid tumors.
    Sigalotti L; Fratta E; Coral S; Maio M
    Pharmacol Ther; 2014 Jun; 142(3):339-50. PubMed ID: 24384533
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.
    Hegde PS; Karanikas V; Evers S
    Clin Cancer Res; 2016 Apr; 22(8):1865-74. PubMed ID: 27084740
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship Between Noncoding RNA Dysregulation and Epigenetic Mechanisms in Cancer.
    Suzuki H; Maruyama R; Yamamoto E; Niinuma T; Kai M
    Adv Exp Med Biol; 2016; 927():109-35. PubMed ID: 27376733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epigenetics of melanoma: implications for immune-based therapies.
    Fratta E; Sigalotti L; Covre A; Parisi G; Coral S; Maio M
    Immunotherapy; 2013 Oct; 5(10):1103-16. PubMed ID: 24088079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New insight into cancer immunotherapy.
    Escribese MM; Barber D
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():50-55. PubMed ID: 29108766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Introduction to checkpoint inhibitors and cancer immunotherapy.
    Sharpe AH
    Immunol Rev; 2017 Mar; 276(1):5-8. PubMed ID: 28258698
    [No Abstract]   [Full Text] [Related]  

  • 51. Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment.
    Yang Y; Wang Y
    Front Immunol; 2021; 12():640369. PubMed ID: 33868269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methylation of immune synapse genes modulates tumor immunogenicity.
    Berglund A; Mills M; Putney RM; Hamaidi I; Mulé J; Kim S
    J Clin Invest; 2020 Feb; 130(2):974-980. PubMed ID: 31714899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epigenetic Regulation of Cancer Immune Cells.
    Avella Patino DM; Radhakrishnan V; Suvilesh KN; Manjunath Y; Li G; Kimchi ET; Staveley-O'Carroll KF; Warren WC; Kaifi JT; Mitchem JB
    Semin Cancer Biol; 2022 Aug; 83():377-383. PubMed ID: 34182142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epigenetics, disease, and therapeutic interventions.
    Lu Q; Qiu X; Hu N; Wen H; Su Y; Richardson BC
    Ageing Res Rev; 2006 Nov; 5(4):449-67. PubMed ID: 16965942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic remodelling of DNA in cancer.
    Lettini AA; Guidoboni M; Fonsatti E; Anzalone L; Cortini E; Maio M
    Histol Histopathol; 2007 Dec; 22(12):1413-24. PubMed ID: 17701921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Epigenetics and cancer].
    Xue C; Yu J; Liu H; Chen J
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Oct; 26(5):1133-6. PubMed ID: 19947505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in epigenetic therapeutics with focus on solid tumors.
    Jin N; George TL; Otterson GA; Verschraegen C; Wen H; Carbone D; Herman J; Bertino EM; He K
    Clin Epigenetics; 2021 Apr; 13(1):83. PubMed ID: 33879235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic modifications in prostate cancer.
    Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
    Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Epigenetics and cancer].
    Deltour S; Chopin V; Leprince D
    Med Sci (Paris); 2005 Apr; 21(4):405-11. PubMed ID: 15811306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
    Bhalla KN
    J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.